2-vinylpyridine

Repeated dose toxicity: inhalation

Administrative data

Endpoint:

sub-chronic toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

4 (not assignable)

Rationale for reliability incl. deficiencies:

other: Older Russian industrial hygiene and toxicology studies do not use international guideline methods, and insufficient data is presented on methods to determine whether they are valid.

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

publication

Title:

On the Toxicology of 2-Vinyl Pyridine

Author:

Dukhovnaya AI

Year:

1966

Bibliographic source:

Gigiena truda (Occupational Hygiene) 3:9-13

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

Accepted chronic inhalation experimental protocol used in Russian scientific institutes, consisting of a 1 week adjustment period with no exposure, 10 weeks of exposure at 4 hours per day, then a 4 week recovery period.

GLP compliance:

not specified

Test material

Test material information

Constituent 1

Reference substance name:

2-vinylpyridine

EC Number:

202-879-8

EC Name:

2-vinylpyridine

Cas Number:

100-69-6

Molecular formula:

C7H7N

IUPAC Name:

2-ethenylpyridine

Details on test material:

Described as a dark brown oily liquid with a pungent and irritating odor. The molecular weight was 105, specific gravity of 0.97 at 20 degrees C, boiling point of 158 degrees C, at 760 mm Hg.

Test animals

Species:

rat

Administration / exposure

Route of administration:

inhalation: vapour

Type of inhalation exposure:

not specified

Details on inhalation exposure:

2VP vapours in a poisoning chamber.

Analytical verification of doses or concentrations:

yes

Duration of treatment / exposure:

4 hours per day

Doses / concentrations

Doses / concentrations 1

Remarks:

Doses / Concentrations:
0.005 mg/L
Basis:
analytical conc.

Doses / concentrations 2

Remarks:

Doses / Concentrations:
0.001 mg/L
Basis:
analytical conc.

No. of animals per sex per dose:

12

Control animals:

yes

Results and discussion

Results of examinations

Body weight and weight changes:

effects observed, treatment-related

Effect levels

Dose descriptor:

NOAEC

Effect level:

0.001 mg/L air (analytical)

Basis for effect level:

other: No change in weight gain or clinical chemistry/haematology

Target system / organ toxicity

Critical effects observed:

not specified

Any other information on results incl. tables

Changes in arterial blood pressure was a major endpoint in this study. The low dose group (0.001 mg/L) displayed a decrease in blood pressure, whereas the high dose group (0.005 mg/L) showed a decrease but with high variability in blood pressure. Nerve /muscle excitability was also measured (no information on methods). There was no difference in nerve/muscle excitability in the low dose group, but there was a decrease in this parameter in the high dose group, where a decrease in nerve/muscle excitability was seen in weeks 4 - 8, then an apparent recovery toward control levels in weeks 9 -13 (which included a cessation of exposure). In the high dose group, there were transient changes in leucocyte and lymphocyte counts, but these returned to control levels during the recovery period. No changes in clinical chemistry values were noted in either dose group. Postmortem examination of the internal organs showed nonspecific changes in the high dose group only. These were described as focal bronchopneumonia, blood vessel dysfunctions and lymphohystiocytic reactive states of parenchymous organs. Focal bronchopneumonia was also found among control animals.

.

Applicant's summary and conclusion

Conclusions:

2-Vinylpyridine was studied in a 10-week inhalation study with a 4 week recovery period, in rats, via an inhalation chamber, at doses of 0, 0.001 mg/L and 0.005 mg/L. The details of this study are not provided; however, other data from this publication are in general agreement with values established using standard guideline methods. Hence, this study has some basis of validity. The NOAEC for rats under these conditions of exposure is 0.001 mg/L.